{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:49:17Z","timestamp":1790272157755,"version":"4.1.0"},"reference-count":21,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.2217\/fon-2023-0272","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T09:22:30Z","timestamp":1696843350000},"page":"131-143","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["<i>In<\/i>\n            -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1518","authenticated-orcid":false,"given":"Robert M","family":"Rifkin","sequence":"first","affiliation":[{"name":"Rocky Mountain Cancer Centers\/US Oncology Research, Denver, CO\ufffd\ufffd80218, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin L","family":"Costello","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Blood &amp; Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA\ufffd\ufffd92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruemu E","family":"Birhiray","sequence":"additional","affiliation":[{"name":"Hematology Oncology of Indiana\/American Oncology Network, Indianapolis, IN\ufffd\ufffd46260, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Kambhampati","sequence":"additional","affiliation":[{"name":"Kansas City Veterans Affairs Medical Center, Kansas City, MO\ufffd\ufffd64128, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY\ufffd\ufffd10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN\ufffd\ufffd46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C","family":"Lee","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center, Houston, TX\ufffd\ufffd77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stokes","sequence":"additional","affiliation":[{"name":"Evidera, Data Analytics, St-Laurent, Quebec, H4T 1V6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Ren","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA\ufffd\ufffd02412, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn Marie","family":"Stull","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA\ufffd\ufffd02421, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasha","family":"Cherepanov","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA\ufffd\ufffd02412, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Bogard","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA\ufffd\ufffd02421, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Noga","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA\ufffd\ufffd02421, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saulius","family":"Girnius","sequence":"additional","affiliation":[{"name":"TriHealth Cancer Institute, Cincinnati, OH\ufffd\ufffd45247, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23933"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2901-x"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0539-0"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.625"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.06.024"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0013"},{"key":"e_1_3_9_11_1","volume-title":"Poster P947 presented at the 27th Congress of the European Hematology Association (EHA) 2022.","author":"Rifkin RM","year":"2022","unstructured":"Rifkin RM , Costello CL , Birhiray RE et al. Comparative Effectiveness of Oral Ixazomib-lenalidomide-dexamethasone (IRd) After Initial Bortezomib (V)-based Induction versus Parenteral V-based Therapy in Newly Diagnosed Multiple Myeloma (NDMM). Poster P947 presented at the 27th Congress of the European Hematology Association (EHA) 2022. Vienna, Austria (9\u201312 June 2022)."},{"issue":"3","key":"e_1_3_9_12_1","first-page":"1605","article-title":"Comparative Effectiveness of Oral Ixazomib-lenalidomide-dexamethasone (IRd) After Initial Bortezomib (V)-based Induction versus Parenteral V-based Therapy in Newly Diagnosed Multiple Myeloma (NDMM). In: Abstract Book for the 27th Congress of the European Hematology Association","volume":"6","author":"Rifkin RM","year":"2022","unstructured":"Rifkin RM , Costello CL , Birhiray RE et al. Comparative Effectiveness of Oral Ixazomib-lenalidomide-dexamethasone (IRd) After Initial Bortezomib (V)-based Induction versus Parenteral V-based Therapy in Newly Diagnosed Multiple Myeloma (NDMM). In: Abstract Book for the 27th Congress of the European Hematology Association. HemaSphere 6(Suppl. 3), 1605\u20131606 (2022).","journal-title":"HemaSphere"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2017.6887"},{"issue":"51","key":"e_1_3_9_14_1","first-page":"849","article-title":"Renal failure\u2013measuring the glomerular filtration rate","volume":"106","author":"Thomas C","year":"2009","unstructured":"Thomas C , Thomas L . Renal failure\u2013measuring the glomerular filtration rate. Dtsch. Arztebl. Int. 106(51-52), 849\u2013854 (2009).","journal-title":"Dtsch. Arztebl. Int."},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S183187"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-019-00184-9"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0724"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125749"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00912-9"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00639"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195794"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:23Z","timestamp":1719125123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.2217\/fon-2023-0272"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0272","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}